Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.68 |
| ▸ | CASP1 | P29466 | 4/20 | 0.68 |
| ▸ | CASP7 | P55210 | 4/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524710 | 0.84 | MAPT (0.70) | MAPTCASP1CASP7TDP1MAPK1 | |
| SCHEMBL5529823 | 0.82 | TSHR (1.00) | MAPTCASP1CASP7TDP1MAPK1 | |
| SCHEMBL14680295 | 0.80 | MAPT (0.74) | MAPTCASP1CASP7TDP1MAPK1 | |
| SCHEMBL24117274 | 0.75 | MAPT (0.69) | MAPTCASP1CASP7TDP1MAPK1 | |
| SCHEMBL9706303 | 0.75 | MAPT (0.50) | MAPTCASP1CASP7TDP1MAPK1 | |
| SCHEMBL13222023 | 0.74 | MAPT (0.51) | MAPTMAPK1ATMKMT2AMEN1 | |
| SCHEMBL1611858 | 0.72 | MAPT (0.47) | MAPTCASP1CASP7TDP1MAPK1 | |
| SCHEMBL24213216 | 0.71 | MAPT (0.59) | MAPTCASP1CASP7TDP1MAPK1 | |
| SCHEMBL9706170 | 0.71 | KMT2A (0.60) | MAPTCASP1CASP7TDP1MAPK1 | |
| Hydrochloric Acid SCHEMBL9706065 | 0.71 | MAPT (0.69) | MAPTCASP1CASP7TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-9220715-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-9119822-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | OMEROS CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-8637528-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2013-10-10 | — | — | US | disclosed |
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2012-05-10 | — | — | US | disclosed |
| US-20100227853-A1 | INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES | TRUSTEES OF BOSTON COLLEGE (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227853-A1 | INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES | TRUSTEES OF BOSTON COLLEGE (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100179158-A1 | INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-15 | — | — | US | disclosed |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | MAPT 3149/4885CASP1 3578/4885CASP7 185/4885 |
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | MAPT 3149/4885CASP1 3578/4885CASP7 185/4885 |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | MAPT 1951/4885CASP1 4458/4885CASP7 449/4885 |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | PARK7, PDE7B, PDE7A | MAPT 1951/4885CASP1 4458/4885CASP7 449/4885 |
| US-20100227853-A1 | INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES | PDE7A, PDE4A, PDE4C | MAPT 3911/4885CASP1 3830/4885CASP7 3426/4885 |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | MAPT 3149/4885CASP1 3578/4885CASP7 185/4885 |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | MAPT 1951/4885CASP1 4458/4885CASP7 449/4885 |
| US-20100179158-A1 | INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES | PDE7A, PDE4A, PDE4C | MAPT 3911/4885CASP1 3830/4885CASP7 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.